Section Arrow
RCEL.NASDAQ
- Avita Medical
Quotes are at least 15-min delayed:2025/08/25 16:58 EDT
After Hours
Last
 4.65
0 (0.00%)
Bid
4.65
Ask
4.67
High 4.65 
Low 4.65 
Volume 1709 
Regular Hours
Last
 4.65
-0.23 (-4.71%)
Day High 
Prev. Close
4.88 
1-M High
6.35 
Volume 
310.20K 
Bid
4.65
Ask
4.67
Day Low
4.58 
Open
4.85 
1-M Low
3.6 
Market Cap 
131.85M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 5.23 
20-SMA 5.26 
50-SMA 5.37 
52-W High 14.16 
52-W Low 3.6 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.97/-0.16
Enterprise Value
176.94M
Balance Sheet
Book Value Per Share
-0.48
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
64.25M
Operating Revenue Per Share
1.51
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PFSAProfusa Inc0.4899-0.0101-2.02%-- 
After Hours 0.61 +0.1201 +24.52%
DXCMDexCom75.96-6.3-7.66%57.93PE
After Hours 76.12 +0.16 +0.21%
BFLYButterfly Network1.55+0.03+1.97%-- 
After Hours 1.6 +0.05 +3.23%
MDTMedtronic plc92.04-0.67-0.72%25.68PE
After Hours 92.04 0 0.00%
ABTAbbott Laboratories131.87-0.72-0.54%16.64PE
After Hours 131.87 0 0.00%
Quotes are at least 15-min delayed:2025/08/25 16:58 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.